Abstract: Described herein is a solid tablet that is directly-compressed of powder, including meloxicam and one or more excipients which are homogenously dispersed within the tablet that can be broken into two, three or four units with each unit containing equal amounts of the active ingredient, meloxicam.
Type:
Grant
Filed:
September 11, 2017
Date of Patent:
May 7, 2019
Assignee:
Boehringer Ingelheim Vetmedica GmbH
Inventors:
Martin A. Folger, Stefan Lehner, Horst Schmitt
Abstract: The present invention relates to methods for treating optic disorders or for reducing or alleviating the signs, symptoms, or pathological conditions related to such optic disorders. In particular, methods are provided for treating optic disorders, or reducing the symptoms thereof, the methods involving the administration of one or more downstream folate compounds and/or methyl-B12. In one particular embodiment, the method comprises administration of L-methylfolate. In other embodiments, the method involves administering both L-methylfolate and methyl-B12. In still further embodiments, the method further involves reducing dietary intake of folic acid. In certain embodiments, the method further involves identifying a subject organism with a malfunction in one or more of the folate or B4 cycles. In certain embodiments, such a malfunction is one or more of the C677T and A1298C mutations.
Abstract: Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting plasma kallikrein. Furthermore, the subject compounds and compositions are useful for the treatment of diseases wherein the inhibition of plasma kallikrein inhibition has been implicated, such as angioedema and the like.
Abstract: The present invention relates to co-crystals of tramadol and co-crystal formers selected from NSAIDs/coxibs, processes for preparation of the same and their uses as medicaments or in pharmaceutical formulations, more particularly for the treatment of pain.
Type:
Grant
Filed:
August 9, 2016
Date of Patent:
April 2, 2019
Assignee:
LABORATORIOS DEL DR. ESTEVE, S.A.
Inventors:
Carlos Ramon Plata Salaman, Nicolas Tesson
Abstract: The present invention relates to co-crystals of tramadol and co-crystal formers selected from NSAIDs/coxibs, processes for preparation of the same and their uses as medicaments or in pharmaceutical formulations, more particularly for the treatment of pain.
Type:
Grant
Filed:
July 12, 2016
Date of Patent:
March 26, 2019
Assignee:
LABORATORIOS DEL DR. ESTEVE, S.A.
Inventors:
Carlos Ramon Plata Salaman, Nicolas Tesson
Abstract: Compounds active on c-kit protein kinases or mutant c-kit protein kinases having any mutations are described, as well as methods of making and using such compounds to treat diseases and conditions associated with aberrant activity of the c-kit protein kinases and mutant c-kit protein kinases.
Type:
Grant
Filed:
September 5, 2013
Date of Patent:
March 12, 2019
Assignee:
Plexxikon Inc.
Inventors:
Jack Lin, John Buell, Katrina Chan, Todd Ewing, Prabha Ibrahim, Marika Nespi, Phuongly Pham, Songyuan Shi, Wayne Spevak, Guoxian Wu, Jiazhong Zhang, Ying Zhang
Abstract: Disclosed herein are compositions and methods for treating ocular diseases, inter alia, diabetic macular edema, age-related macular degeneration (wet form), choroidal neovascularization, diabetic retinopathy, retinal vein occlusion (central or branch), ocular trauma, surgery induced edema, surgery induced neovascularization, cystoid macular edema, ocular ischemia, uveitis, and the like. These diseases or conditions are characterized by changes in the ocular vasculature whether progressive or non-progressive, whether a result of an acute disease or condition, or a chronic disease or condition.
Abstract: A method of treating polycystic kidney disease in a subject comprises administering to the subject an effective amount of a compound represented by Structural Formula (1): or a pharmaceutically acceptable salt thereof.
Type:
Grant
Filed:
January 25, 2017
Date of Patent:
March 5, 2019
Assignee:
Genzyme Corporation
Inventors:
Thomas A. Natoli, Oxana Ibraghimov-Beskrovnaya, John P. Leonard, Nelson S. Yew, Seng H. Cheng
Abstract: An aqueous formulation for topical application to the skin comprising water, a water-miscible organic solvent, and benzoyl peroxide, wherein the concentration of the organic solvent is sufficient to provide a stable suspension of benzoyl peroxide in the aqueous formulation without the inclusion of a surfactant in the formulation, wherein the ratio of concentrations of water and organic solvent in the formulation is sufficient to maintain the benzoyl peroxide in saturated solubility in the formulation following application to the skin, and wherein the concentration of benzoyl peroxide in the formulation is less than 5.0% and at least 1.0% w/w. The formulation may further contain a chemical compound in addition to benzoyl peroxide that is effective in the treatment of acne. The aqueous formulations of the invention are useful in the treatment of acne and acne rosacea.
Abstract: Compositions and methods for lightening skin are provided. A method for lightening skin may include the step of identifying skin where lightening or whitening is desired and topically applying to the skin a composition including (a) a skin lightening agent comprising a canola extract and (b) a cosmetically acceptable carrier. A method for treating hyperpigmentation may include the step of identifying skin containing areas of hyperpigmentation and topically applying to the skin a composition including (a) a canola extract and (b) a cosmetically acceptable carrier.
Abstract: The present invention relates generally to the cosmetic treatment of aged skin. More specifically, the invention relates to the use of ingenol compounds, particularly ingenol angelates, in treating photo-aged and/or chronologically-aged skin.
Type:
Grant
Filed:
February 12, 2010
Date of Patent:
December 4, 2018
Assignee:
LEO Laboratories Limited
Inventors:
Steven Martin Ogbourne, David Thomas, Ryan Moseley, James Harrison Aylward
Abstract: The present invention relates to imidazole compounds, and pharmaceutically acceptable compositions thereof, useful as positive allosteric modulators of follicle stimulating hormone receptor (FSHR).
Type:
Grant
Filed:
June 24, 2014
Date of Patent:
November 27, 2018
Assignee:
Merck Patent GmbH
Inventors:
Henry Yu, Thomas E. Richardson, Marianne Donnelly, Ngan Nguyen, Xuliang Jiang
Abstract: An aqueous formulation for topical application to the skin comprising water, a water-miscible organic solvent, and benzoyl peroxide, wherein the concentration of the organic solvent is sufficient to provide a stable suspension of benzoyl peroxide in the aqueous formulation without the inclusion of a surfactant in the formulation, wherein the ratio of concentrations of water and organic solvent in the formulation is sufficient to maintain the benzoyl peroxide in saturated solubility in the formulation following application to the skin, and wherein the concentration of benzoyl peroxide in the formulation is less than 5.0% and at least 1.0% w/w. The formulation may further contain a chemical compound in addition to benzoyl peroxide that is effective in the treatment of acne. The aqueous formulations of the invention are useful in the treatment of acne and acne rosacea.
Type:
Grant
Filed:
October 24, 2016
Date of Patent:
November 27, 2018
Assignee:
Dow Pharmaceutical Sciences, Inc.
Inventors:
Yunik Chang, Gordon J. Dow, Radhakrishnan Pillai
Abstract: Described herein are pharmaceutical compositions including a proton pump inhibitor and an antiparasitic drug. In some embodiments, the compositions can be formulated as a non-solid for oral administration. The compositions can be used to treat gastrointestinal conditions. Methods of treatment using the compositions are also described.
Type:
Grant
Filed:
August 11, 2017
Date of Patent:
November 27, 2018
Assignee:
Adamis Pharmaceuticals Corporation
Inventors:
David Clayton Sutherland, James Kyle Zorn, Dennis J. Carlo
Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of SOC channel activity.
Type:
Grant
Filed:
May 20, 2016
Date of Patent:
October 23, 2018
Assignee:
CALCIMEDIA, INC.
Inventors:
Jeffrey P. Whitten, Jonathan Grey, Jianguo Cao, Zhijun Wang, Evan Rogers
Abstract: The present invention provide chemical modulators of insect olfactory receptors. In particular, compounds and compositions are provided that can inhibit host targeting functions in insects such as mosquitos. Method of employing such agents, and articles incorporating the same, are also provided.
Type:
Grant
Filed:
April 7, 2016
Date of Patent:
October 9, 2018
Assignee:
Vanderbilt University
Inventors:
Laurence Zwiebel, Gregory M. Pask, David Rinker, Patrick L. Jones
Abstract: The present disclosure relates to compositions including a fatty acid soap/fatty acid mixture, and methods of use thereof. The compositions include a C5 to C12 fatty acid or mixtures thereof. The compositions show increased activity, e.g., insecticidal, soil removal, antimicrobial activity, at a controlled pH range of about 7.5 to about 9.0.
Type:
Grant
Filed:
May 20, 2013
Date of Patent:
October 9, 2018
Assignee:
Ecolab USA Inc.
Inventors:
Victor Fuk-Pong Man, Yvonne Marie Killeen, Michael Charles DeNoma, Kelly J. Herrera, S. John Barcay, William J. Pattison
Abstract: A tetrazolinone compound represented by formula (1): wherein R1 represents a C1-C6 alkyl group; R2, R3, and R4 are the same or different and represent a hydrogen atom; R5 represents a C1-C3 alkyl group optionally having one or more halogen atoms; Y represents #āC(RA 1 RA 2)āZā in which left end and Q are bound to each other, and RA 1 and RA 2 each represents a hydrogen atom; Q represents a divalent C3-C10 carbocyclic group; X represents an oxygen atom; and A represents a C6-C10 aryl group, has excellent control activity against pests.
Abstract: Active compounds useful for inhibiting fatty acid synthase in a subject in need thereof are described. The active compounds are, in general, a 5-mercapto-1H-Indazole-4,7-dione or an analog thereof. The compounds are useful for treating subjects afflicted with, cancer, obesity, diabetes, a viral infection, a bacterial infection, a fungal infection, or a protozoal infection.
Type:
Grant
Filed:
June 27, 2016
Date of Patent:
September 11, 2018
Assignee:
Wake Forest University Health Sciences
Inventors:
Steven J. Kridel, W. Todd Lowther, Herman H. Odens, Jeffrey D. Schmitt